Literature DB >> 9849979

Etiology of childhood pneumonia: serologic results of a prospective, population-based study.

T Heiskanen-Kosma1, M Korppi, C Jokinen, S Kurki, L Heiskanen, H Juvonen, S Kallinen, M Stén, A Tarkiainen, P R Rönnberg, M Kleemola, P H Mäkelä, M Leinonen.   

Abstract

BACKGROUND: To investigate the etiology of pediatric community-acquired pneumonia, we conducted a prospective, population-based study covering the total population <15 years of age (n = 8851) in 4 municipalities in eastern Finland.
MATERIALS AND METHODS: The number of patients was 201; chest radiographs were available for all cases and paired sera for serologic assays were available for >90% of cases. The methods included assays for antibody response to 3 pneumococcal antigens, specific pneumococcal immune complex assays and conventional antibody tests for mycoplasmal, chlamydial and viral infections.
RESULTS: Serologic evidence of specific microbial etiology was obtained in 133 (66%) of the pneumonia patients. Bacterial infection was diagnosed in 102 cases (51%) and viral infection in 51 cases (25%). Streptococcus pneumoniae was the most common agent (57 cases; 28%), followed by Mycoplasma pneumoniae (44; 22%), respiratory syncytial virus (43; 21%) and Chlamydia spp. (29; 14%). Haemophilus influenzae was identified in only 6% and Moraxella catarrhalis in only 3% of the children. More than one specific infection was found in 51 patients (25%). The proportion of pneumococcal cases varied from 24 to 36% by age. Mycoplasma infections were seen mostly in patients > or =5 years and Chlamydia infections in patients > or =10 years of age.
CONCLUSIONS: The results of our prospective, strictly population-based study confirm the importance of S. pneumoniae in the etiology of community-acquired pneumonia in children of all ages. M. pneumoniae and Chlamydia pneumoniae are important from the age of 5 years onwards.

Entities:  

Mesh:

Year:  1998        PMID: 9849979     DOI: 10.1097/00006454-199811000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  62 in total

Review 1.  New pneumococcal vaccines for children.

Authors:  S Choo; A Finn
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

2.  Streptococcus pneumoniae and Mycoplasma pneumoniae coinfection in community acquired pneumonia.

Authors:  P Toikka; T Juvén; R Virkki; M Leinonen; J Mertsola; O Ruuskanen
Journal:  Arch Dis Child       Date:  2000-11       Impact factor: 3.791

3.  Errors in registered birth weight and its implications for mortality statistics.

Authors:  D Anand; P O Pharoah
Journal:  Arch Dis Child       Date:  2000-11       Impact factor: 3.791

4.  British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Childhood.

Authors: 
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

5.  Mycoplasma pneumoniae in Community-Acquired Lower Respiratory Tract Infections.

Authors:  Surinder Kumar; Indu Bala Garg; Gulshan Rai Sethi
Journal:  Indian J Pediatr       Date:  2018-01-10       Impact factor: 1.967

Review 6.  Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review.

Authors:  Victor van der Meer; Arie Knuistingh Neven; Peterhans J van den Broek; Willem J J Assendelft
Journal:  BMJ       Date:  2005-06-24

7.  Mycoplasma pneumoniae infection complicated by necrotizing pneumonitis with massive pleural effusion.

Authors:  Chih-Yung Chiu; Lin-Mei Chiang; Tzu-Ping Chen
Journal:  Eur J Pediatr       Date:  2006-01-19       Impact factor: 3.183

Review 8.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children?

Authors:  Dilshad Ahmad Khan; Aisha Rahman; Farooq Ahmad Khan
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 10.  Community-acquired pneumonia in children: issues in optimizing antibacterial treatment.

Authors:  Matti Korppi
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.